Acurx Pharmaceuticals Secures $7.1 Million in At-the-Market Offering

Event summary

  • Acurx Pharmaceuticals raised $2.5 million upfront via a registered direct offering, with potential for an additional $4.6 million from short-term warrants.
  • The offering involved 825,085 shares of common stock (or pre-funded warrants) sold at $3.03 per share.
  • Short-term warrants for up to 1,650,170 shares were issued with an exercise price of $2.78 per share, exercisable immediately and expiring in 24 months.
  • Proceeds will be used for working capital and general corporate purposes.
  • The offering is expected to close on April 16, 2026.

The big picture

Acurx Pharmaceuticals' $7.1 million offering reflects the ongoing need for late-stage biopharmaceutical companies to secure non-dilutive financing to support clinical trials and operational expenses. The deal underscores the strategic importance of maintaining liquidity in a competitive sector where R&D costs are high and regulatory hurdles are significant. The inclusion of short-term warrants adds a layer of financial flexibility, though the actual proceeds will depend on market conditions and investor sentiment.

What we're watching

Execution Risk
Whether Acurx can successfully advance its Phase 3 clinical trials for ibezapolstat, given the reliance on securing additional financing.
Market Dynamics
How the additional capital will impact Acurx's ability to compete in the crowded antibiotics market.
Financial Strategy
The pace at which the short-term warrants will be exercised, determining the total funds raised.

Related topics

Biotechnology